Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904397 · ClinicalTrials.gov registry record · Phase 4
Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain
A Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
NCT00904397: Clinical Trial Phase 4 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00904397 is a Phase 4 study that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 98 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904397, a Phase 4 study, was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
Study Summary
Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation.
Interventions
- DRUG Celecoxib
- DRUG Lidoderm®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2004-07 |
| Phase | Phase 4 |
Why NCT00904397 stopped before completion
NCT00904397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT00904397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00904397 about?
NCT00904397 is a clinical study titled "Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain". Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chro...
What is the current status of trial NCT00904397?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2004-07.
What interventions are being tested in trial NCT00904397?
The interventions under investigation include: Celecoxib (DRUG), Lidoderm® (DRUG).
Who is sponsoring clinical trial NCT00904397?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00904397's enrollment target sits among peer trials
98 854th of 2000 higher than 1,140 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia